Posts

Posted on

Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

PR Newswire

TARRYTOWN, N.Y. and PARIS, Nov. 30, 2020 /PRNewswire/ —

Pivotal trial showed more than four times as many children achieved itch reduction and more than three times as many children achieved clear or almost clear skin with Dupixent plus topical corticosteroids (TCS) compared to TCS alone

Nearly three in four children achieved a 75% improvement in disease extent and severity, with an average improvement of approximately 80%

Approximately 80% of children experienced clinically meaningful improvements in a composite of health-related quality of life measures that include sleep, school, emotional well-being and relationships

Expanded approval of Dupixent for these children reinforces well-established, long-term safety profile

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has extended the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients.

“As the parent of a child with atopic dermatitis, and someone who works with families impacted by this condition daily, I’ve seen first-hand the enormous physical and mental health burden of this disease, and the toll it can take on the entire family,” said Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research (GPER). “Young children with severe atopic dermatitis currently have few treatment choices and significant unmet needs. We welcome the addition of new medicines for these underserved patients.”

Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating, and severe disease can significantly impact many aspects of life for both children and their families. The current standard of care for children with severe atopic dermatitis in Europe is limited to topical treatments, leaving those with poorly-controlled disease to cope with intense, unrelenting itch and skin lesions that can cover much of the body, resulting in skin cracking, redness or darkening, crusting and oozing. In addition, uncontrolled severe atopic dermatitis can have a substantial emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression and feelings of isolation in children.

“This approval for Dupixent in the EU represents a major advancement for children with severe atopic dermatitis and their families, who spend countless days and nights tending to their child’s disease with few treatment options to help alleviate the debilitating symptoms,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron. “Dupixent is a novel therapy that addresses a root cause of atopic dermatitis by specifically targeting the underlying type 2 inflammation of the disease. Dupixent has already been used by hundreds of thousands of patients around the world, including those with atopic dermatitis as well as other type 2 inflammatory diseases such as asthma and adults with chronic rhinosinusitis with nasal polyps. We are pleased to bring this paradigm-changing medicine to even younger patients in the EU who need new options beyond steroids or immunosuppressants.”

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, that was invented using Regeneron’s proprietary VelocImmune® technology, and is not an immunosuppressant. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).

“The approval of Dupixent for children in Europe marks another significant milestone for atopic dermatitis patients and their families, broadening the availability of a first-in-class medicine that offers a proven safe and effective treatment for this debilitating skin disease,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. “Dupixent’s ability to provide significantly clearer skin, and clinically meaningful reduction of persistent itch, addresses important unmet needs for these children. In addition to atopic dermatitis, we continue to investigate the potential of Dupixent in younger age groups and across a variety of type 2 inflammatory diseases.”

In children aged 6 to 11 years weighing 15 to <60 kg, Dupixent 300 mg is administered as an injection under the skin (subcutaneous injection) every four weeks following the initial loading dose given as two injections 14 days apart. For those weighing ≥60 kg, Dupixent 300 mg is administered every two weeks following the initial loading dose given the same day. The dose may be increased to 200 mg every two weeks in patients weighing 15 to <60 kg based on physician’s assessment.

The EC decision is based primarily on data that includes pivotal Phase 3 efficacy and safety results of Dupixent combined with topical corticosteroids (TCS) compared to TCS alone (placebo) in children 6 to 11 years with severe atopic dermatitis. At 16 weeks, patients in treatment groups of Dupixent 300 mg every four weeks (N=122) or 200 mg every two weeks (N=59) with TCS experienced:

— Improved disease extent and severity:

  • 82% average improvement from baseline with Dupixent every four weeks compared to 49% for placebo.
  • 80% average improvement from baseline with Dupixent every two weeks compared to 48% for placebo.
  • 70% of patients in the every four week treatment group achieved at least a 75% improvement compared to 17% for placebo.
  • 75% of patients in the every two week treatment group achieved at least a 75% improvement compared to 26% for placebo.

— Skin clearance: 

  • 33% of patients achieved clear or almost clear skin with Dupixent every four weeks compared to 11% for placebo.
  • 39% of patients achieved clear or almost clear skin with Dupixent every two weeks compared to 10% for placebo.

— Reduced itch:

  • 51% of patients achieved clinically significant reduction of itch with Dupixent every four weeks compared to 12% for placebo.
  • 61% of patients achieved clinically significant reduction of itch with Dupixent every two weeks compared to 13% for placebo.
  • A significantly greater proportion of Dupixent patients achieved improvement in itch as early as four weeks.

— Improved health-related quality of life (HR-QoL):

  • 77% of patients experienced clinically meaningful improvement in patient-reported HR-QoL with Dupixent every four weeks compared to 39% for placebo.
  • 81% of patients experienced clinically meaningful improvement in patient-reported HR-QoL with Dupixent every two weeks compared to 36% for placebo.
  • Dupixent patients also experienced improvements in additional HR-QoL measures assessing disease severity and patient-reported measures such as itch and sleep.

The safety profile of Dupixent in children 6 to 11 years of age followed through week 52, based on an open-label extension trial, was similar to the safety profile observed at week 16 and consistent with the safety profile seen in adults and adolescents with atopic dermatitis. Overall rates of adverse events (AEs) were 65% and 61% for Dupixent every four and two weeks, respectively, and 73% and 75% for placebo. AEs that were more commonly observed with Dupixent included upper respiratory tract infections (11% and 9% for Dupixent every four and two weeks, 10% and 12% for placebo), injection site reactions (10% and 14% for Dupixent every four and two weeks, 6% and 5% for placebo), nasopharyngitis (13% and 3% for Dupixent every four and two weeks, 7% and 10% for placebo), conjunctivitis (7% and 9% for Dupixent every four and two weeks, 4% and 5% for placebo), and fever (3% for both Dupixent groups, 2% and 0% for placebo). Additional prespecified AEs included skin infections (6% and 9% for Dupixent every four and two weeks, 13% for both placebo groups), and herpes viral infections (2% for both Dupixent groups, 5% for both placebo groups).

About the Pediatric Trial
The co-primary endpoints in the pediatric trial were skin clearance, as measured by a score of 0 or 1 on the Investigator’s Global Assessment (IGA), and disease extent and severity, as measured by Eczema Area and Severity Index score (EASI-75).

Secondary endpoints included the average change in EASI score from baseline, and itch as measured by at least a 4-point reduction in itch intensity on a 0 to 10-point scale (weekly average of daily Peak Pruritus Numerical Rating Scale). Additionally, HR-QoL was measured by the proportion of patients who achieved at least six points on the patient-reported Children’s Dermatology Life Quality Index (CDLQI), as well as additional measures from Patient Oriented Eczema Measure (POEM) and SCORing Atopic Dermatitis (SCORAD).

About Dupixent
 
Dupixent is approved for specific patients with atopic dermatitis, asthma and/or in adults with CRSwNP in a number of countries around the world, including the European Union, U.S. and Japan. Dupixent is currently approved in more than 60 countries, and more than 200,000 patients have been treated globally.

Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home by self-administration after training by a healthcare professional. In children younger than 12 years of age, Dupixent should be administered by a caregiver. No initial lab testing or ongoing lab monitoring is required with Dupixent treatment in any approved indication or age group.

Dupilumab was invented using Regeneron’s VelocImmune® technology that utilizes a proprietary genetically-engineered mouse platform endowed with a genetically-humanized immune system to produce optimized fully-human antibodies. VelocImmune technology has been used to create multiple antibodies including Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab) and Kevzara® (sarilumab), which are approved in multiple countries around the world. Regeneron previously used these technologies to rapidly develop a treatment for Zaire ebolavirus infection, which is approved by the FDA, and to create a potentially preventative and therapeutic investigational medicine for COVID-19 that was recently granted Emergency Use Authorization (EUA).

Dupilumab Development Program
To date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven by type 2 inflammation.

In addition to the currently approved indications, Regeneron and Sanofi are also studying dupilumab in a broad range of diseases driven by type 2 inflammation and other allergic pathways, including pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), pediatric asthma (6 to 11 years of age, Phase 3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2). These potential uses are investigational, and the safety and efficacy of dupilumab in these conditions have not been evaluated by any regulatory authority. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

U.S. Indications
DUPIXENT is a prescription medicine used:

  • to treat people aged 6 years and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 years of age.
  • with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems. It is not known if DUPIXENT is safe and effective in children with asthma under 12 years of age.
  • with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyposis under 18 years of age.

I
M
PORTANT SAFETY INFORMATION FOR U.S. PATIENTS

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

— have eye problems
— have a parasitic (helminth) infection
— are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with DUPIXENT.
— are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.

  • There is a pregnancy exposure registry for women who take DUPIXENT during pregnancy to collect information about the health of you and your baby. Your healthcare provider can enroll you or you may enroll yourself. To get more information about the registry call 1–877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/.

— are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.  

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis or CRSwNP, and also have asthma. Do not change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.

DUPIXENT can cause serious side effects, including:

  • Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: breathing problems, fever, general ill feeling, swollen lymph nodes, swelling of the face, mouth and tongue, hives, itching, fainting, dizziness, feeling lightheaded (low blood pressure), joint pain, or skin rash.
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.
  • I
    n
    flammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by DUPIXENT. Tell your healthcare provider right away if you have: rash, shortness of breath, persistent fever, chest pain, or a feeling of pins and needles or numbness of your arms or legs.

T
h
e most common side effects by indication are as follows:

  • Atopic dermatitis: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, and cold sores in your mouth or on your lips.
  • Asthma: injection site reactions, pain in the throat (oropharyngeal pain), and high count of a certain white blood cell (eosinophilia).
  • C
    h
    r
    on
    i
    c rhinosinusitis with nasal polyposis: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, high count of a certain white blood cell (eosinophilia), trouble sleeping (insomnia), toothache, gastritis, and joint pain (arthralgia).

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed. Your healthcare provider will tell you how much DUPIXENT to inject and how often to inject it. DUPIXENT is an injection given under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give DUPIXENT injections, you or your caregiver should receive training on the right way to prepare and inject DUPIXENT. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider. In children 12 years of age and older, it is recommended that DUPIXENT be administered by or under supervision of an adult. In children younger than 12 years of age, DUPIXENT should be given by a caregiver.

Please see full 

Prescribing Information 

including Patient Information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Regeneron Forward-Looking Statements and Use of Digital Media 
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron’s business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron’s and its collaborators’ ability to continue to conduct research and clinical programs, Regeneron’s ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators (collectively, “Regeneron’s Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron’s Products and Regeneron’s product candidates and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab); uncertainty of market acceptance and commercial success of Regeneron’s Products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron’s Products (such as Dupixent) and product candidates; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s product candidates and new indications for Regeneron’s Products, such as dupilumab for the treatment of pediatric atopic dermatitis, pediatric asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, food and environmental allergies, and other potential indications; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and product candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and product candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent, and Praluent® (alirocumab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the quarterly period ended September 30, 2020.  Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Sanofi Forward-Looking Statements 
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2018. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Regeneron Contacts:




Media Relations


Hannah Kwagh

Tel: + (914) 847-6314


[email protected]


Investor Relations


Mark Hudson

Tel: +1 (914) 847-3482


[email protected]


Sanofi Contacts:



Media Relations


Sally Bain

Tel.: +1 (781) 264-1091


[email protected]


Investor Relations
Sanofi Investor Relations – Contacts
Paris


Eva Schaefer-Jansen

Arnaud Delepine

Yvonne Naughton


Sanofi Investor Relations – Contacts
North America


Felix Lauscher

Fara Berkowitz

Suzanne Greco



Sanofi IR main line:


Tel.: +33 (0)1 53 77 45 45


[email protected] 


https://www.sanofi.com/en/investors/contact

 

Cision View original content:http://www.prnewswire.com/news-releases/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-atopic-dermatitis-301181374.html

SOURCE Regeneron Pharmaceuticals, Inc.

Posted on

EIB supports AB Science in its COVID-19 development programme

Paris, 30 November 2020, 7am 

EIB supports AB Science in its COVID-19 development programme

  • Financing deal worth €15.0 million signed to support clinical development programme for masitinib
  • Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available

AB Science SA (Euronext – FR0010557264 – AB) and the European Investment Bank (the EIB) are pleased to announce the signing of a loan agreement totalling €15.0 million (the COVID-19 loan) today.

This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.

Masitinib might be an effective treatment for COVID-19 due to its recently discovered dual mechanism allowing it to act as both an anti-inflammatory and an antiviral agent. Masitinib directly inhibits the 3CL protease, the main protease of SARS-CoV-2 directly involved in the replication of the virus.

This initial partnership with the EIB might be expanded in the future, as discussions are already underway about additional financing for other indications in which masitinib is or could be evaluated, for a maximum budget of €30.0 million.

This financing is supported by the European Fund for Strategic Investments, the financial centrepiece of the Investment Plan for Europe under which the EIB and European Commission have joined forces to kick-start priority investments in the European Union. It is also backed by the InnovFin risk-sharing mechanism which targets corporate research initiatives supported by Horizon 2020, the European Union’s framework programme for research and innovation.

The combination of the EIB’s expertise and the European Commission’s support with the InnovFin guarantee has made it possible to set up an innovative financing package tailor-made to the needs of AB Science.

The COVID-19 loan consists of two tranches of €6 million each, and a third tranche worth €3 million. The first tranche is expected to be released in the coming weeks. The remaining two tranches will be made available at a later stage, subject to certain milestones, including clinical progress in AB Science’s study regarding the treatment of COVID-19 and the company’s future equity funding.

The COVID-19 loan is supplemented by an agreement to issue warrants for the EIB. The number of warrants to be issued by AB Science each time a tranche of the COVID-19 loan is drawn will depend on its reference price prior to the disbursement and the amount of the tranche in question. Purely as an illustration, a reference price of €10.0 would mean that AB Science should issue 162,162 warrants when it draws the first tranche. Each warrant will entitle the EIB to subscribe to one ordinary share in AB Science at the reference price (discount of 5.0%) for a period of 15 years.

Each time a tranche of the COVID-19 loan is drawn, AB Science will issue a press release specifying the terms and conditions and the final number of warrants issued on the occasion.

Alain Moussy, co-founder and chief executive of AB Science, said: “This is an important agreement because this major loan is a sign of a leading European institution’s interest in the development of masitinib. The EIB loan supporting masitinib’s development as a treatment for COVID-19 demonstrates that masitinib is a credible candidate thanks to its dual antiviral and anti-inflammatory mechanism. We hope that this first agreement is only the beginning of a long partnership with the European Investment Bank, allowing us to move faster in developing new medicines for diseases where therapeutic solutions are not available or insufficient.”

“I am delighted to announce this funding agreement with AB Science. The fight against COVID-19 is a priority for the European Union’s bank, which is why we support the development of therapeutic options that could provide an effective response to the health crisis,” said EIB Vice-President Ambroise Fayolle. He added, “Small and medium-sized enterprises are a major source of medical innovation that we need to build on. That’s why it is important that we support and work with them.”

Against the backdrop of the health crisis, this new financing reflects the EIB’s strong mobilisation to support the development of new and effective treatments for COVID-19. This new funding takes total European investment to €600 million in support of 19 biotechs and medtechs involved in the fight against the epidemic.

Note to editors

About the European Investment Bank

Created by the Treaty of Rome and founded in 1958, the EIB is the European Union’s bank, which, together with its dedicated SME support subsidiary the European Investment Fund (EIF), forms the EIB Group. The EIB Group is a key player in reviving Europe’s – including France’s – economy through investment. Thanks to its reliable expertise and the financial attractiveness of its AAA rating, the EIB Group has strengthened its activities in France since 2012 (reaching €8.5 billion of investment in 2019), not only supporting businesses and innovation but also financing projects in strategic sectors such as climate action, energy, healthcare, housing, education for young people and training infrastructure. The EIB Group is the operator of the Investment Plan for Europe, commonly known as the Juncker Plan.

To find out more about the EIB: www.eib.org

InnovFin – EU Finance for Innovators
– Under Horizon 2020, the EU research and innovation programme for 2014-2020, the European Commission and the European Investment Bank Group (EIB and EIF) launched a new generation of financial instruments and advisory services in 2014 to help innovative firms access finance more easily. Until the end of 2020, the InnovFin – EU Finance for Innovators programme is offering a range of customised products providing financing support for research and innovation projects conducted by small, medium-sized and large companies and promoters of research infrastructure.

About masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, which are important cells for immunity, by inhibiting a limited number of kinases. Thanks to its unique mechanism, masitinib can be developed for a large number of medical conditions including cancer, inflammatory diseases, and certain diseases of the central nervous system. In oncology, masitinib has the potential to improve survival when administered alone or in combination with chemotherapy, thanks to its immunotherapeutic properties.

Masitinib can alleviate symptoms in certain inflammatory disorders and central nervous system diseases by acting on mast cells and microglia, thereby inhibiting the activation of the inflammatory process.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a class of targeted proteins whose action is key in signalling pathways within cells. Our programmes only target diseases which have high unmet medical needs, are often lethal with short-term survival, or are rare or refractory to a previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

To find out more about AB Science: www.ab-science.com

Press contacts

AB Science

Financial communication and press relations
[email protected]		 European Investment Bank

Anne-Cécile Auguin: +352 621 361948
[email protected]
Press Office: +352 4379 21000
[email protected]

 


Forward-looking statements – AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates, as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words “expect,” “anticipate,” “believe,” “intend,” “estimate,” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorisations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 “Risk Factors” of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

 

This press release and the information contained therein do not constitute an offer for subscription or purchase, or the solicitation of a purchase or subscription order, of AB Science securities in the United States or in any other jurisdiction in which the transaction may be subject to restrictions. This press release is a promotional communication and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council, as amended. The distribution or publication of this press release in certain countries may be subject to restrictions under the legal and regulatory provisions in force. Accordingly, persons present in these countries where this press release is distributed or published must inform themselves of and comply with these laws and regulations.

Attachment



Posted on

Update on the intended offer by Sanofi for Kiadis

This is a joint press release by Sanofi (“Sanofi“) and Kiadis Pharma N.V. (“Kiadis“), pursuant to the provisions of Section 7, paragraph 1 sub a of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree“) in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer“). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum (the “Offer Document“) approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) (the “AFM“) and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) (the ”FSMA”). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Update on the intended offer by Sanofi for Kiadis


Paris, France and Amsterdam, The Netherlands, 30 November 2020 – Sanofi (Euronext:


SAN and NYSE: SNY) and Kiadis Pharma N.V. (“Kiadis” or the “Company”)

(Euronext Amsterdam and Brussels: KDS)

Reference is made to the joint press release by Sanofi and Kiadis dated 2 November 2020 in respect of the Offer to be made by Sanofi at an offer price of EUR 5.45 in cash per share (cum dividend).

Pursuant to the provisions of Section 7, paragraph 1 sub a of the Decree, requiring a public announcement including a status update regarding an intended public offer within four weeks following its announcement, Sanofi and Kiadis hereby provide this joint update on the Offer.

Sanofi and Kiadis confirm that they are making good progress on the preparations for the Offer. At the date of this press release, Sanofi will submit a request for review and approval of the offer document in relation to the Offer with the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financiële Markten).

In addition, Sanofi and Kiadis confirm that the process to obtain the required competition clearance for the Offer is proceeding. Sanofi and Kiadis anticipate that the Offer will close in the first half of 2021.

Dutch Translation/Nederlandse vertaling


Parijs, Frankrijk en Amsterdam, Nederland, 30 november 2020 – Sanofi (Euronext:


SAN en NYSE: SNY) en Kiadis Pharma N.V. (“Kiadis” of de “Vennootschap”) (Euronext Amsterdam en Brussels: KDS)

Verwezen wordt naar het gezamenlijk persbericht van Sanofi en Kiadis van 2 november 2020 met betrekking tot het voorgenomen openbaar bod (het Bod) dat door Sanofi zal worden uitgebracht tegen een biedprijs van EUR 5,45 in contanten (cum dividend) per aandeel.

Ingevolge het bepaalde in artikel 7 lid 1 sub a van het Besluit openbare biedingen Wft, waarin is bepaald dat binnen vier weken na aankondiging van een voorgenomen openbaar bod een openbare mededeling is vereist met daarin een update over dat bod, verstrekken Sanofi en Kiadis hierbij deze gezamenlijk voornoemde update met betrekking tot het Bod. 

Sanofi en Kiadis bevestigen dat ze goede voortgang boeken met de voorbereidingen van het Bod. Vandaag zal Sanofi een verzoek tot beoordeling en goedkeuring van het biedingsbericht indienen bij de Autoriteit Financiële Markten.

Verder bevestigen Sanofi en Kiadis dat het proces om de benodigde toezichtrechtelijke goedkeuring te verkrijgen voor het Bod vordert. Sanofi en Kiadis verwachten dat het Bod zal worden afgerond in de eerste helft van 2021.

Dit is een samenvatting van het Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.

For more information:

Kiadis:

Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305
[email protected]

Kiadis Media Relations Contacts
LifeSpring Life Sciences Communication:
Leon Melens (Amsterdam)
Tel: +31 538 16 427
[email protected]

Optimum Strategic Communications:
Mary Clark, Supriya Mathur
Tel: +44 203 950 9144
[email protected]

 Sanofi
:

Sanofi Media Relations Contact


Ashleigh Koss
Tel.: +1 (908) 205-2572
[email protected]

Sanofi Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine
Yvonne Naughton

Sanofi Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco

IR main line:
Tel.: +33 (0)1 53 77 45 45
[email protected]

About Kiadis

Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.Kiadis.com.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. Sanofi prevents illness with vaccines and provides innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Disclaimer

This is a joint public announcement by Kiadis and Sanofi pursuant to section 7 paragraph 1 sub a and contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

The information in the press release is not intended to be complete. This announcement is for information purposes only and does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities.

The distribution of this press release may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions. To the fullest extent permitted by applicable law, Sanofi and Kiadis disclaim any responsibility or liability for the violation of any such restrictions by any person. Any failure to comply with these restrictions may constitute a violation of the securities laws of that jurisdiction. Neither Sanofi, nor Kiadis, nor any of their advisors assumes any responsibility for any violation by any of these restrictions. Any Kiadis shareholder who is in any doubt as to his or her position should consult an appropriate professional advisor without delay.


Kiadis Forward-Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.


Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Sanofi’s ability to complete the acquisition on the proposed terms or on the proposed timeline, the possibility that competing offers will be made, other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.



Posted on

Daqo New Energy Announces Long-Term High-Purity Polysilicon Supply Agreement with Trina Solar

PR Newswire


SHANGHAI
, Nov. 30, 2020 /PRNewswire/ — Daqo New Energy Corp. (NYSE: DQ) (“Daqo New Energy”, the “Company” or “we”), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced that it signed a long-term high-purity polysilicon supply agreement with Trina Solar (SSE:688599) (“Trina”), a global leading solar PV system integrator.

Under the supply agreement, Daqo New Energy will provide Trina with high-purity mono-grade polysilicon in a total amount of 30,000 MT ~ 37,600 MT between November 2020 and December 2023. Actual prices will be negotiated by both parties monthly according to market conditions. As part of the supply agreement, Trina will make an advance payment to Daqo New Energy.

Mr. Jifan Gao, Chairman of Trina Solar, commented, “As a global leading solar PV solution provider, we are always committed to innovation and quality improvement. We are pleased to enter into a long-term partnership with Daqo New Energy. This will help us better execute our strategy, which is to provide advanced solar PV products and solutions with higher efficiency so as to address fast growing demand in solar PV market, drive grid parity and benefit society through green energy.”

Mr. Longgen Zhang, Chief Executive Officer of Daqo New Energy, commented, “We are very pleased to deepen our cooperation with Trina Solar with this three-year polysilicon supply agreement. We will continue to provide first-class polysilicon products to our customers and work with them to facilitate innovation, improve conversion efficiency, reduce levelized cost and achieve grid-parity for solar PV energy.

About Trina Solar

Founded in 1997 as a world leading solar PV system integrator, Trina Solar’s business includes R&D, manufacture and sales of solar PV modules, power plants and system products, solar PV power generation and operations and maintenance and service, R&D and sales of smart micro-grid, multi-energy system, and smart energy cloud platform operations.

About Daqo New Energy

Daqo New Energy Corp. (NYSE: DQ) (“Daqo” or the “Company”) is a leading manufacturer of high-purity polysilicon for the global solar PV industry. Founded in 2007, the Company is one of the world’s lowest cost producers of high-purity polysilicon. Daqo’s highly-efficient and technically advanced manufacturing facility currently has a nameplate annual polysilicon production capacity of 70,000 metric tons.

For more information, please visit www.dqsolar.com

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the demand for photovoltaic products and the development of photovoltaic technologies; global supply and demand for polysilicon; alternative technologies in cell manufacturing; the Company’s ability to significantly expand its polysilicon production capacity and output; the reduction in or elimination of government subsidies and economic incentives for solar energy applications; the Company’s ability to lower its production costs; changes in the political and regulatory environment; and the duration of COVID-19 outbreaks in China and many other countries and the impact of the outbreaks and the quarantines and travel restrictions instituted by relevant governments on economic and market conditions, including potentially weaker global demand for solar PV installations that could adversely affect the Company’s business and financial performance. Further information regarding these and other risks is included in the reports or documents the Company has filed with, or furnished to, the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date hereof, and the Company undertakes no duty to update such information or any forward-looking statement, except as required under applicable law.

Cision View original content:http://www.prnewswire.com/news-releases/daqo-new-energy-announces-long-term-high-purity-polysilicon-supply-agreement-with-trina-solar-301181406.html

SOURCE Daqo New Energy Corp.

Posted on

Datto Expands Global Sales Leadership to Accelerate MSP Partner Growth

Datto Expands Global Sales Leadership to Accelerate MSP Partner Growth

New leaders in APAC and EMEA drive move to managed services model for SME IT

READING, England–(BUSINESS WIRE)–Datto Holding Corp.(“Datto”) (NYSE: MSP), the leading global provider of cloud-based software and technology solutions purpose-built for delivery by managed service providers (MSPs), today announced several key sales leadership appointments across Asia Pacific (APAC) and Europe, the Middle East and Africa (EMEA). As the MSP technology company, Datto expanded its sales leadership team to help empower MSPs with the IT resources and added expertise required to meet the increasing and accelerating digital transformation needs of the (Small and Medium Enterprises) SME market in 2021.

Leadership in APAC:

Datto welcomes Danny Mesrop as Vice President of Sales, APAC, to establish and grow Datto’s go-to-market strategy in the Asia-Pacific region. Mesrop brings years of experience leading successful sales programmes and channel relationships to Datto. Prior to joining, he was Regional Vice President, Channels & Alliances for Asia Pacific at Akamai Technologies. After over a decade of being based in Singapore, Mesrop will relocate to the Datto office in Sydney, Australia.

To assist Mesrop in expanding partner growth in the Asia-Pacific region, Datto is pleased to announce the promotion of Tom Fernandez as Regional Sales Manager, Asia. Fernandez joined Datto in 2013 and brings years of proven team leadership, sales expertise, and successful MSP partner relations to his new role. Fernandez has recently relocated to the Datto Singapore office in order to better serve MSP partners.

Leadership in EMEA:

Datto welcomes James Vyvyan as Vice President of Sales, EMEA, where he will oversee company growth in the region and manage Datto’s EMEA sales leadership team. Vyvyan began his career in the British Army and reached the rank of Captain before making the move into the corporate realm. Most recently, he spent 13 years at Sophos, managing teams in the channel before he moved on to lead the UK team, where he was ultimately promoted to Senior Vice President of EMEA Sales.

Also in EMEA, Datto welcomes Michael Gutsch as Regional Sales Manager, DACH. Here he will be responsible for the extension of sales, growth of the MSP partner network, and strategic go-to-market activities in the DACH region. Gutsch started his career with Dell where he led Dell’s eBusiness in the German market and was also responsible for End User Computing Brand & Merchandising for Germany. Most recently, he worked as Head of MSP CEEMEA at Sophos where he helped build the MSP Channel for Sophos in the region.

“Prioritising word-class sales talent with experience in forging relationships across the globe is a top priority for Datto,” said Sanjay Singh, Chief Revenue Officer. “Datto has been very clear in its commitment to helping global IT providers transform to the managed services model. Making real investments in regional leadership and resources is a core part of that promise. I’m very pleased to be able to welcome our new sales leaders as they drive our teams to support the accelerated growth of MSP partners in markets across the globe.”

About Datto

As the world’s leading provider of cloud-based software and technology solutions purpose-built for delivery by managed service providers (MSPs), Datto believes there is no limit to what small and medium businesses can achieve with the right technology. Datto offers Unified Continuity, Networking, and Business Management solutions and has created a unique ecosystem of MSP partners. These partners provide Datto solutions to over one million businesses across the globe. Since its founding in 2007, Datto has won awards for its rapid growth, product excellence, superior technical support, and for fostering an outstanding workplace. With headquarters in Norwalk, Connecticut, Datto has global offices in the United Kingdom, the Netherlands, Denmark, Germany, Canada, Australia, China, and Singapore. Learn more at www.datto.com.

MSP-C

Media:

Shoba V. Lemoine

[email protected]

KEYWORDS: Asia Pacific United Kingdom Europe Middle East Africa

INDUSTRY KEYWORDS: Networks Security Data Management Technology Software

MEDIA:

Logo
Logo
Posted on

Nano Dimension Prices $60 Million Registered Direct Offering

Sunrise, Florida, Nov. 29, 2020 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leading Additively Manufactured Electronics (“AME”)/PE (Printed Electronics) provider, today announced it has entered into definitive agreements with investors for the sale of 11,960,160 of the Company’s American Depositary Shares (“ADSs”) at a price of $5.00 per ADS pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $60 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds for working capital and for other general corporate purposes, and pursuing strategic opportunities, including possible business combination transactions. The closing of the registered direct offering is expected to take place on or about December 2, 2020, subject to the satisfaction of customary closing conditions.

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-249559) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and an additional registration statement pursuant to Rule 462(b) under the Securities Act of 1933, as amended. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, Telephone: (877) 436-3673; Email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nano Dimension

Nano Dimension (Nasdaq: NNDM) is a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). High fidelity active electronic and electromechanical subassemblies are integral enablers of autonomous intelligent drones, cars, satellites, smartphones, and in vivo medical devices. They necessitate iterative development, IP safety, fast time-to-market and device performance gains, thereby mandating AME for in-house, rapid prototyping and production. Nano Dimension machines serve cross-industry needs by depositing proprietary consumable conductive and dielectric materials simultaneously, while concurrently integrating in-situ capacitors, antennas, coils, transformers and electromechanical components, to function at unprecedented performance. Nano Dimension bridges the gap between printed circuit board and semiconductor integrated circuits. A revolution at the click of a button: From computer-aided design (CAD) to a functional high-performance AME device in hours, solely at the cost of the consumable materials. 

For more information, please visit 

www.nano-di.com

.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nano Dimension is using forward-looking statements in this press release when it discusses expected timing of the closing of the offering and planned use of the net proceeds from the offering. Because such statements deal with future events and are based on Nano Dimension’s current expectations, they are subject to various risks and uncertainties. Actual results, performance or achievements of Nano Dimension could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Nano Dimension’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 10, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Nano Dimension is not responsible for the contents of third-party websites.

NANO DIMENSION INVESTOR RELATIONS CONTACT

Yael Sandler, CFO | [email protected]



Posted on

Global Care Capital Evaluates Opportunities in the Crypto Currency and Blockchain Sectors

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Nov. 29, 2020 (GLOBE NEWSWIRE) — Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that it is evaluating investment opportunities in the crypto currency and blockchain sectors.

In addition to continuing to evaluate opportunities in the healthcare sector, the Company has commenced its due diligence and research procedures in search of new investment opportunities in the crypto currency and blockchain sectors to diversify and strengthen its existing portfolio. The Company’s management team and board of directors will remain the same as it pursues opportunities in these sectors.

The initiative by the company to evaluate crypto currency and blockchain investment opportunities is a reflection of its focus on innovative new markets. The company is moving forward to explore exciting new opportunities in crypto currency and blockchain and hopes to find additional investments in the near future.

About Global Care

Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.

www.globalcarecapital.com

GLOBAL CARE CAPITAL
INC
.:


Company Contact:
 

Company Contact:
Alex Somjen, President & CEO
604-687-2038

[email protected]

The CSE does not accept responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com



Posted on

LIXIL Redefining Corporate Culture through Transformation

~ Announces simplified job titles to drive greater Empowerment throughout the organization

PR Newswire

SINGAPORE, Nov. 30, 2020 /PRNewswire/ — LIXIL, maker of pioneering water and housing products, today announced that as a part of ongoing measures to simplify the organization and shift to a more agile culture, it is simplifying titles for managers and above across the entire organisation. For managers across LIXIL International and working in global roles at corporate functions, titles will be standardized as “Leader” along with area of responsibility.

The timing of the move is in line with ongoing transformation initiatives, including divestment of non-core businesses and the merger of LIXIL Group and LIXIL Corporation to shift to a simplified operating company structure. Through a series of transformational exercises, LIXIL is embedding a more agile, empowering, and open culture that enables employees to succeed to their full potential.

LIXIL is now taking a transformational step to remove barriers to agility and ensure the focus stays on the work, by standardizing titles as ‘Leader’ along with their area of responsibility, effective 1 December 2020.

Along with the simplification of titles, this year LIXIL has also redefined the role of Corporate Officers to consist of one President and two classes of Officers: Executive Vice President and Senior Vice President, bringing the number of Corporate Officers down from 50 to 24. This change has also clarified the roles and responsibilities of the top leadership team with fiduciary responsibility for managing and setting the direction of the company, thereby strengthening governance.


Bijoy Mohan, Leader at LIXIL International, said,“This is a highly visible milestone towards a simpler, more empowered and non-hierarchical culture. What’s important is the actual work individuals are responsible for, not the title or rank they carry. We are focused on strengthening agile, team-based work. Teams create value for the organization by capitalizing on the collective strengths and diversity of thought, which will be made possible when we have an environment that does away with deference to hierarchy, fear of consequences, and lack of transparency. We want the best ideas to win, rather than a person’s rank. My leadership team and I are committed to making this change a meaningful one.”

With this change, LIXIL also aims to better serve its partners and consumers, by placing an even greater focus on the services provided, instead of the title that the employees carry. Ultimately, LIXIL aims to build a more agile and innovative organisation that can quickly adapt to changes in an ever-evolving world, and one that understands and meets consumers’ fast changing needs, which will be critical in enabling sustainable growth.

About LIXIL

LIXIL makes pioneering water and housing products that solve everyday, real-life challenges, making better homes a reality for everyone, everywhere. Drawing on our Japanese heritage, we create world-leading technology and innovate to make high-quality products that transform homes. But the LIXIL difference is how we do this; through meaningful design, an entrepreneurial spirit, a dedication to improving accessibility for all, and responsible business growth. Our approach comes to life through industry leading brands, including INAX, GROHE, American Standard, and TOSTEM. Over 60,000 colleagues operating in more than 150 countries are proud to make products that touch the lives of more than a billion people every day. Learn more at www.lixil.com

LIXIL Group Corporation (TSE Code: 5938) is the listed holding company for LIXIL’s portfolio of businesses.

Cision View original content:http://www.prnewswire.com/news-releases/lixil-redefining-corporate-culture-through-transformation-301181391.html

SOURCE LIXIL

Posted on

Toyoda Gosei Invests in Ball Wave, a Startup from Tohoku University

Toyoda Gosei Invests in Ball Wave, a Startup from Tohoku University

KIYOSU, Japan–(BUSINESS WIRE)–
Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested1 in Ball Wave Inc., a startup from Tohoku University that develops practical applications of ball SAW sensors.2 These sensors use natural collimation of surface acoustic waves (SAWs), a physical phenomenon predicted and experimentally verified by researchers at Tohoku University, and can instantly detect various kinds of matter in air and other gases at the nanoscale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201129005111/en/

Ball SAW sensor (Graphic: Business Wire)

Ball SAW sensor (Graphic: Business Wire)

Toyoda Gosei and Ball Wave will leverage Toyoda Gosei’s surface treatment technologies, such as painting and plating technology cultivated in the development and production of automotive interiors and exteriors, to achieve coatings for better ball SAW sensor performance. In the future, the two companies aim to develop a sensor that can detect viruses in the air with a view to combining it with Toyoda Gosei’s deep UV LED technology that can eliminate the novel coronavirus and other viruses.

Toyoda Gosei will continue to tackle social issues through collaboration with startups that are promising for synergy with its core technologies.

*1

100 million yen was invested in November 2020.

*2

Ball Wave has commercialized devices such as a high-performance trace moisture sensor that can be used in semiconductor manufacturing processes and drying rooms.

Company outline of Ball Wave

Company name

Ball Wave Inc.

Headquarters

Tohoku University Business Incubator T-Biz 501, 6-6-40, Aza Aoba, Aramaki, Aoba, Sendai, Miyagi

President & CEO

Dr. Shingo Akao

Founded

November, 2015

Capital

JPY100 million (as of October, 2020)

 

Toyoda Gosei Co., Ltd.

Takatomo Abe

[email protected]

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Semiconductor Automotive Manufacturing Manufacturing Technology Nanotechnology University Small Business Education Professional Services Infectious Diseases Aftermarket Science Automotive Health Research

MEDIA:

Logo
Logo
Photo
Photo
Ball SAW sensor (Graphic: Business Wire)
Posted on

Chris Brown Wins Big at the 2020 “Soul Train Awards” Hosted by Tisha Campbell and Tichina Arnold

Chris Brown Wins Big at the 2020 “Soul Train Awards” Hosted by Tisha Campbell and Tichina Arnold

Young Thug and H.E.R. Also Bring Home Top Honors

The Award Show Featured Performances by Lady of Soul Honoree Monica, Brandy, Ella Mai, Jazmine Sullivan, Snoh Aalegra and CeeLo Green With Duets by Charlie Wilson & Smokey Robinson and Lucky Daye & Babyface

—

Red Carpet Images: HERE

Show Images: HERE

Performances: HERE

—

#SOULTRAINAWARDS

NEW YORK–(BUSINESS WIRE)–
The 2020 “Soul Train Awards” celebrated the best in soul, R&B and hip hop by highlighting both living legends and breakout stars with unrivaled musical moments and show-stopping performances. The awards show, which aired this evening, November 29, 2020 at 8 PM EST on BET, BET Her, VH1 and MTV2 was hosted by the iconic best friend duo Tisha Campbell and Tichina Arnold, who also brought their chemistry to the stage as the show’s opening musical acts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201129005429/en/

Tichina Arnold and Tisha Campbell Host The 2020 Soul Train Awards on BET (Photo: Business Wire)

Tichina Arnold and Tisha Campbell Host The 2020 Soul Train Awards on BET (Photo: Business Wire)

Chris Brown led the pack as the evening’s most awarded artist, dominating in four categories including Best R&B/Soul Male Artist and the shared honors of Song of the Year, Best Dance Performance and Best Collaboration with Young Thug for their hit “Go Crazy.” H.E.R. followed closely with two awards: Best R&B/Soul Female Artist and The Ashford & Simpson Songwriter’s Award for “I Can’t Breathe.

Honoring artists across 12 categories, the 2020 “SOUL TRAIN AWARDS” also recognized Summer Walker (Album of the Year), Megan Thee Stallion (Rhythm & Beats Award), Brandy (Soul Train Certified), Beyoncé, Blue Ivy, Saint Jhn & Wizkid (Video of the Year), Snoh Aalegra (Best New Artist) and Kirk Franklin (Best Gospel/Inspirational Award) for their special contributions to the genre.

The hosts kicked things off with an electrifying song and dance tribute to the power of Black women. Brandy performed a medley of her recent hits “Say Something” and “Boderline.” Ella Mai sang her latest single “Not Another Love Song.” Lucky Daye shut the stage down with Babyface for a performance of their new collaboration “Shoulda.” Charlie Wilson performed a duet with Smokey Robinson before honoring the memory of gospel legend Rance Allen with a rousing tribute. Additional performers included Jazmine Sullivan, Snoh Aalegra and CeeLo Green. After accepting the Lady of Soul Award, Monica brought down the house with a jam-packed performance of her chart-topping hits.

In addition to electrifying performances, this year’s highly anticipated Soul Cypher featured R&B stars PJ Morton, Chanté Moore, Shanice and Stokely. Ella Nicole and Moses Sumney took the BET Amplified Music Stage, a platform for emerging artists. Presenters included Andra Day, Tessa Thompson, Nnamdi Asomugha, Deon Cole, Nicco Annan, Dallas Austin, Jermaine Dupri and Brandee Evans.

The full winners list for 2020 “SOUL TRAIN AWARDS” is below:

2020 “SOUL TRAIN AWARDS” WINNERS

Best New Artist – Snoh Aalegra

Soul Train Certified Award –Brandy

Best R&B/Soul Male Artist – Chris Brown

Best R&B/Soul Female Artist – H.E.R.

Video of the Year – Beyoncé, Blue Ivy, Saint Jhn & Wizkid “Brown Skin Girl”

Best Gospel/Inspirational Award – Kirk Franklin

Album of the Year – Summer Walker “Over It”

Rhythm & Bars Award – Megan Thee Stallion “Savage”

Song of the Year – Chris Brown & Young Thug “Go Crazy”

The Ashford & Simpson Songwriter’s Award – “I Can’t Breathe,” Written by H.E.R.

Best Dance Performance – Chris Brown & Young Thug “Go Crazy”

Best Collaboration Performance – Chris Brown & Young Thug “Go Crazy”

Connie Orlando, EVP Specials, Music Programming & Music Strategy at BET, along with Jesse Collins, CEO of Jesse Collins Entertainment (JCE), and JCE’s Jeannae Rouzan–Clay and Dionne Harmon will Executive Produce the 2020 “SOUL TRAIN AWARDS.”

For show information, please visit BET.com/SoulTrain, the official site for 2020 “SOUL TRAIN AWARDS.”

ABOUT BET

BET, a subsidiary of ViacomCBS Inc. (NASDAQ: VIACA, VIAC), is the nation’s leading provider of quality entertainment, music, news, and public affairs television programming for the African-American audience. The primary BET channel is in 90 million households and can be seen in the United States, Canada, the Caribbean, the United Kingdom, sub-Saharan Africa, and France. BET is the dominant African-American consumer brand with a diverse group of business extensions including BET.com, a leading Internet destination for Black entertainment, music, culture, and news; BET HER, a 24-hour entertainment network targeting the African-American Woman; BET Music Networks – BET Jams, BET Soul and BET Gospel; BET Home Entertainment; BET Live, BET’s growing festival business; BET Mobile, which provides ringtones, games and video content for wireless devices; and BET International, which operates BET around the globe.

ABOUT JESSE COLLINS ENTERTAINMENT

Jesse Collins Entertainment (JCE) is a full-service television and film production company and has played an integral role in producing many of television’s most memorable moments in music entertainment. JCE has a multi-year overall agreement with ViacomCBS Cable Networks. On the theatrical film side, the company also has a first look on JCE’s film development projects which could include Viacom’s film entities such as Paramount Players. The award-winning and critically acclaimed television that JCE has produced includes miniseries—The New Edition Story and The Bobby Brown Story; scripted series—American Soul and Real Husbands of Hollywood; children’s series—Bookmarks: Celebrating Black Voices; award shows—BET Awards, Black Girls Rock!, BET Honors, UNCF’s An Evening of Stars, BET Hip Hop Awards, ABFF Honors and Soul Train Awards; specials—John Lewis: Celebrating A Hero, Love & Happiness: An Obama Farewell, Change Together: From The March On Washington To Today, Stand Up for Heroes, Dear Mama, Amanda Seales I Be Knowin’, Def Comedy Jam 25 and Leslie Jones: Time Machine; as well as competition/game shows—Sunday Best, Hip Hop Squares, Nashville Squares and Rhythm & Flow. Jesse Collins, founder & CEO of the company, is the executive producer of all programming and is also a producer for the iconic Grammy Awards. He will next executive produce The Pepsi Super Bowl LV Halftime Show. Go to jessecollinsent.com for more information on the company.

ABOUT SOUL TRAIN HOLDINGS

SOUL TRAIN HOLDINGS, LLC was formed in May 2008 and is owned by InterMedia Partners and a partnership between Magic Johnson Enterprises and Ron Burkle’s investment firm, The Yucaipa Companies. The iconic franchise and catalog consists of more than 1,100 episodes and 40 specials from Don Cornelius Productions, Inc. Soul Train is the longest running, first-run, nationally syndicated music program in television history. During its 35-year run, the show featured lasting innovations such as the Soul Train line and the legendary sign off “Love, Peace and Soul.” At the heart of the show was Don Cornelius, the dancers and influential artists such as James Brown, Al Green, Ike & Tina Turner, Hall & Oates, Donna Summer, Marvin Gaye, The Jackson 5, Aretha Franklin, Stevie Wonder, Elton John, Whitney Houston, David Bowie, Prince, Run D.M.C. and Destiny’s Child.

Follow us @BET_PR

BET MEDIA

LeToya Glenn-Bacon

[email protected]

(212) 205-3158

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Women Men TV and Radio Music General Entertainment Events/Concerts Consumer Entertainment

MEDIA:

Photo
Photo
Tichina Arnold and Tisha Campbell Host The 2020 Soul Train Awards on BET (Photo: Business Wire)